Co-trimoxazole

Phase 3Small molecule

UUniversity College, London

Co-trimoxazole is one of 129 small molecule programs targeting Abscess. It is currently in Phase 3.

Indications

Total Trials

Active Trials

128

Competitors

Pipeline

Status by Indication[3][1]

Indication

AbscessActive, not recruiting

PneumoniaActive, not recruiting

PeritonitisActive, not recruiting

COVID-19Active, not recruiting

AbscessPhase 2/Phase 3

Active, not recruiting

PneumoniaPhase 2

Active, not recruiting

PeritonitisPhase 3

Active, not recruiting

COVID-19Phase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Co-trimoxazole

UUniversity College, London

Phase 3

2 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Aldactone

Pfizer

Preclinical

1 7

Nexavar

Bayer

Preclinical

1 8

Stivarga

Bayer

Preclinical

1 9

Singulair

AstraZeneca

Preclinical

1 10

Aimovig

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2/3Recruiting

Abscess

NCT04310930

Clinical

Trials by Indication[1]

COVID-192 trials

The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients

Completed·—·Phase 2/3·NCT04884490·94 enrolled

Role of Co-trimoxazole in Severe COVID-19 Patients

Unknown status·—·Phase 2·NCT04470531·94 enrolled

Pneumonia1 trial

Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults

Recruiting·MMundipharma Research Limited·Phase 2·NCT05835479·50 enrolled

Trial1 trial

Nepal Undifferentiated Febrile Illness Trial

Completed·OOxford University Clinical Research Unit, Vietnam·Phase 3·NCT02773407·330 enrolled

Abscess1 trial

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Recruiting·TThe University of Queensland·Phase 2/3·NCT04310930·300 enrolled

Peritonitis1 trial

Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis

Unknown status·UUniversity College, London·Phase 3·NCT04395365·442 enrolled

1 more indication

Unspecified1 trial

Pharmacokinetic Parameters of Co-trimoxazole

Completed·UUniversity Medical Center Groningen·Phase 2·NCT01832987·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Co-trimoxazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Co-trimoxazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Co-trimoxazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University College, London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity College, London

Co-trimoxazole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

COVID-192 trials

Pneumonia1 trial

Trial1 trial

Abscess1 trial

Peritonitis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News